- Conditions
- Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
- Biological · Other
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Interventions
- RP2, RP3, atezolizumab, bevacizumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Seattle, Washington
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- 4D-125 IVT Injection, Observational
- Biological · Other
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 5 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- MeiraGTx UK II Ltd
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • Atlanta, Georgia + 3 more
- Conditions
- Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
- Interventions
- Observational study with no interventions
- Other
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-RPGR
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 8 Years to 50 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-RPGR
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 6 Years to 50 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Durham, North Carolina • Cincinnati, Ohio • Portland, Oregon + 1 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- AAV5-hRKp.RPGR, No intervention (Follow-Up assessment)
- Biological · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- BIIB112
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more
- Conditions
- Advanced Solid Tumor
- Interventions
- RP3, Nivolumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
- Interventions
- Adeno-associated virus vector expressing a human RPGR gene
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Miami, Florida • Durham, North Carolina + 3 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-hRPGRco, Control
- Biological · Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- AAV5-hRKp.RPGR
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Genetic: AAV5-hRKp.RPGR
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- AAV5-RPGR
- Genetic
- Lead sponsor
- MeiraGTx UK II Ltd
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Genetic: AAV5-hRKp.RPGR Intermediate Dose, Genetic: AAV5-hRKp.RPGR Low Dose
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more